Sinovac's Covid-19 vaccine candidate approved for emergency use in China

China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceuti­cal (Sinopharm), also said it had obtained emergency use approval for a vaccine candidate

Sinovac Biotech Ltd's coronavirus vaccine candidate CoronaVac was approved in July for emergency use as part of a programme in China to vaccinate high-risk groups such as medical staff, a person familiar with the matter said.

China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceuti­cal (Sinopharm), also said it had obtained emergency use approval for a coronavirus vaccine candidate in social media platform WeChat on Sunday. CNBG, which has two vaccine candidates in phase 3 clinical trials, did not say which of its vaccines had been cleared for emergency use.

China has been giving experimental coronavirus vaccines to high-risk groups since July, and a health official told state media in an interview aired last week that authorities could consider modestly expanding the emergency use programme to try to prevent possible outbreaks during the autumn and winter.

Officially, China has given little details on which vaccine candidates have been given to high-risk people.

China-backed AIIB gives $100 mn loan to Bangladesh

Beijing-backed Asian Infrastructure Investment Bank said on Friday it will lend $100 million to Ban­gladesh to help the country deal with the Covid-19 pandemic.  Reuters

Moderna, Japan in talks for 40 mn vaccine doses

Moderna said it was in talks with Japan's government to potentially supply 40 million doses of its Covid-19 vaccine candidate. The vaccine candidate, mRNA-1273, would be distributed by Takeda Pharm. Reuters